InMed Pharmaceuticals is focused on developing proprietary small molecule drug candidates that target the CB1 and CB2 receptors, with a pipeline that includes treatments for Alzheimer’s disease, age-related macular degeneration, epidermolysis bullosa, and glaucoma. Their lead candidate, INM-901, has shown promising neuroprotective effects and the ability to reduce neuroinflammation in preclinical studies, indicating its potential as a treatment for Alzheimer’s disease. Additionally, InMed is advancing INM-755, a cannabinol (CBN) topical cream that has completed a Phase 2 clinical trial for epidermolysis bullosa, and is developing INM-088, a CBN formulation for glaucoma, which is currently in preclinical stages.

InMed's subsidiary, BayMedica, specializes in the manufacturing of rare cannabinoids, producing high-purity ingredients such as cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), and cannabidivarin (CBDV) for the health and wellness industry. The company has developed a library of patentable cannabinoid analogs, which are being screened for their therapeutic properties. InMed's extensive patent portfolio and collaborations with cannabinoid experts position the company as a leader in the therapeutic development of rare cannabinoids, exploring their unique physiological effects and potential applications in treating various diseases.

Canada

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three drug development programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Nasdaq: INM

InMed Pharmaceuticals

Company Details